From a treatment response perspective, the blink reflex may have utility as a biomarker; Anzellotti and colleagues investigated the effect of the cholinesterase inhibitor donepezil upon the blink reflex response in 26 DLB patients and 20 AD patients (Anzellotti et al., 2008). This evidence concerns the gene BCHE and Lewy body dementia.